Seattle Genetics is making waves in the biotech industry of Washington state. This innovative company is not only growing under the leadership of President Clay Siegall, it is thriving in the pharmaceutical markets becoming the number one drug company in Washington. This recent growth had attracted the attention of many powerful players in the business world. His unique business plan has overseen the development of multiple drugs set to release near one another. While this is different from some biotechnology companies, it allows Seattle Genetics to expand their research into treatments for different types of cancers.
In a recent article by Sally James published on Seattlebusinessmag.com, Clay Siegall discussed the four drugs he feels will have the most promise in the upcoming release. The most promising, Adcetris is already approved by the Food and Drug Administration as a secondary treatment for Hodgkin’s Lymphoma. Pending successful testing, this drug might be catapulted to the first line of defense for these cancers which is something that has Siegall and Seattle Genetics very excited. In addition to Adcetris, Seattle Genetics is also working on 33A to treat acute myeloid leukemia, 22ME for bladder cancer, and LIV1 which may be a treatment for breast cancer. While these drugs are still in development, Siegall is confident that they will make some contribution to the oncology community.
While Siegall is the president of Seattle Genetics, he is also the co-founder, chairman, and CEO of the large pharmaceutical company. Because of his personal interest in Seattle Genetics, he is excited at the prospect of new growth within the company. Currently, Seattle Genetics is exploding in growth with spending on research increasing by over 60% at almost $400 million this year alone. Credit for such growth can go to Siegall because he has adequately applied his knowledge of the biotechnology field to successfully grow his company, increasing its value dramatically.
As Siegall makes the decisions for his company, he relies on his extensive education and experience. He holds a Ph.D. in Genetics from George Washington University and countless other experiences that bolster his knowledge within the pharmaceutical field. He sits as a chairman on the boards of several other pharmaceutical companies and uses his connections to help build lasting relationships. While his company is still growing and ready to burst into the big pharmacology arena, it is clear that they have a ringer in their corner with Clay Siegall.